Scilex Holding Company Interest Expense Nonoperating
Scilex Holding Company (SCLX) reported Interest Expense Nonoperating of $6.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-14
- Scilex Holding Company interest expense nonoperating for the quarter ending 2026-06-30 was $6.10M, a 127.59% increase year-over-year.
- Scilex Holding Company interest expense nonoperating for the quarter ending 2026-03-31 was $3.78M, a 52.32% increase year-over-year.
- Scilex Holding Company interest expense nonoperating for the quarter ending 2025-12-31 was $3.50M, a 1127.37% increase year-over-year.
- Scilex Holding Company interest expense nonoperating for the quarter ending 2025-09-30 was $2.80M, a 385.76% increase year-over-year.
- Scilex Holding Company interest expense nonoperating for fiscal 2025 was $11.46M, a 483.75% increase from fiscal 2024.
- Scilex Holding Company interest expense nonoperating for fiscal 2024 was $1.96M, a 83.80% increase from fiscal 2023.
- Scilex Holding Company interest expense nonoperating for fiscal 2023 was $1.07M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.10M 10-Q · filed 2026-08-14 | $11.56M 10-Q · filed 2026-08-14 | $13.38M derived: sum of 3 quarters · filed 2026-08-14 | $16.18M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $3.78M 10-Q · filed 2026-05-20 | $7.28M derived: sum of 2 quarters · filed 2026-05-20 | $10.07M derived: sum of 3 quarters · filed 2026-05-20 | $12.76M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $6.30M derived: sum of 2 quarters · filed 2026-04-10 | $8.98M derived: sum of 3 quarters · filed 2026-08-14 | $11.46M 10-K · filed 2026-04-10 |
| 2025-09-30 | $2.80M 10-Q · filed 2025-11-14 | $5.48M derived: sum of 2 quarters · filed 2026-08-14 | $7.96M 10-Q · filed 2025-11-14 | $8.25M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.68M 10-Q · filed 2026-08-14 | $5.16M 10-Q · filed 2026-08-14 | $5.45M derived: sum of 3 quarters · filed 2026-08-14 | $6.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.48M 10-Q · filed 2026-05-20 | $2.77M derived: sum of 2 quarters · filed 2026-05-20 | $3.34M derived: sum of 3 quarters · filed 2026-05-20 | $3.91M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $285.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $861.00K derived: sum of 2 quarters · filed 2026-04-10 | $1.43M derived: sum of 3 quarters · filed 2026-04-10 | $1.96M 10-K · filed 2026-04-10 |
| 2024-09-30 | $576.00K 10-Q · filed 2025-11-14 | $1.15M derived: sum of 2 quarters · filed 2025-11-14 | $1.68M 10-Q · filed 2025-11-14 | $2.23M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $571.00K 10-Q · filed 2025-08-13 | $1.10M 10-Q · filed 2025-08-13 | $1.65M derived: sum of 3 quarters · filed 2025-08-13 | $2.17M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $531.00K 10-Q · filed 2025-05-14 | $1.08M derived: sum of 2 quarters · filed 2025-05-14 | $1.59M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $551.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.06M derived: sum of 2 quarters · filed 2025-03-31 | $1.07M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $513.00K 10-Q · filed 2025-01-17 | $517.00K 10-Q · filed 2025-01-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |